To compare levels of brevican, neurocan, aggrecan and HAPLN1 in subcellular fractions of different areas of AD and control brains we used a total set of 19 brain samples grouped into three diagnostic groups (control, high-grade AD = ADhigh, and low-grade AD = ADlow) according to clinical AD diagnosis criteria. This evidence concerns the gene ACAN and Alzheimer disease.